Market Overview
- The Global Prurigo Nodularis Treatment Market is expected to grow at a CAGR of 3.6% during the forecasting period (2020-2027).
- Prurigo Nodularis (PN) is a skin disease that causes hard, itchy lumps to form on the skin. There exists an intense itching which cause people to scratch till bleeding or pain. Prurigo nodularis may serve as a phenotypic presentation of several underlying disease like atopic dermatitis, chronic kidney disease-related pruritus, and neurological diseases.
Download free sample: https://www.datamintelligence.com/download-sample/prurigo-nodularis-treatment-market
Market Dynamics
- The major driving forces are the presence of favorable regulations and initiatives for orphan drug development in various regions, increasing healthcare expenditure, the rarity of the disease, rising demand for prominent orphan drugs used to treat rare diseases.
- The presence of an increased number of research and development activities is expected to drive the market over the forecast period. For instance, according to an article published on August 26, 2019, Johns Hopkins researchers estimated the real-world prevalence of prurigo nodularis. In the study, they identified 7,095 people with PN, 23,882 with atopic dermatitis without PN, and 38,283 with psoriasis without PN. Based on these numbers, they have calculated that more than 72 per 100,000 people are affected with PN, primarily females with an average age of 50 years.
- The presence of a strong product pipeline is also expected to drive the market over the forecast period. For instance,
- However, the availability of alternative treatment options and shortage of skilled healthcare professionals are the factors expected to hinder the growth of the prurigo nodularis treatment market over the period of forecast.
- The availability of alternative treatment options is hindering the market growth. For instance, Pimecrolimus was as effective as hydrocortisone and offered an alternative topical treatment option that may be implemented in a long-term regimen. Phototherapy can be used for the treatment of several inflammatory skin conditions and is a therapeutic alternative for patients with multiple comorbidities or generalized prurigo nodularis.
Market Segmentation Analysis
- By product type, the prurigo nodularis treatment market can be segmented into corticosteroids, emollients, capsacin cream, antihistamines, and others.
- The corticosteroid creams segment is expected to witness substantial growth during the forecast years. Considerable segmental growth can be attributed to the advantages possessed by these creams. These topical corticosteroids control the spread of fungal skin infection and decrease inflammation to a greater extent. Also, creams, when applied externally on the body surface, provides faster relief as compared to the oral tablets, which require time to show outcomes. Further, the presence of ongoing research and development activities is expected to drive the market growth. For instance,
Market Geographical Analysis
- Geographically, the global prurigo nodularis treatment market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
- Western Europe is dominating the global prurigo nodularis treatment market in 2018 and is estimated to hold significant market size over the forecast period (2020-2027) owing to the presence of key initiatives, ongoing research and development activities, and the presence of leading vendors operating in the region. For instance,
Market Competitive Trends
- The major players operating in the global prurigo nodularis treatment market are Menlo Therapeutics Inc., Pfizer, Kiniksa Pharmaceuticals, Ltd., GlaxoSmithKline, Galderma, Trevi Therapeutics, and Celgene Corporation.
- The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the prurigo nodularis treatment market globally. For instance,
- On October 12, 2019, Pfizer Inc. announced the complete results from a Phase III, 12-week, pivotal study (JADE MONO-1) in patients of age 12 and older with moderate to severe atopic dermatitis (AD). Abrocitinib, an investigational oral Janus kinase 1 (JAK1) inhibitor, met all the co-primary and key secondary endpoints, which were related to skin clearance and itch relief compared to placebo.
- On March 8, 2019, Galderma, Nestlé Skin Health's medical solutions business, presented the results from a Phase IIb dose-ranging study of nemolizumab, an investigational therapy in adult patients with moderate-to-severe atopic dermatitis, at the breaking session of the 2019 American Academy of Dermatology annual meeting.
- On March 8, 2017, Menlo Therapeutics Inc. announced that the Phase 2 trial (TCP-102) assessing serlopitant for pruritus (itch) associated with prurigo nodularis (PN) successfully met its primary efficacy endpoint and secondary endpoints, demonstrating a significant reduction in pruritus (p<0.001 for the primary efficacy analysis at week 8) in the subjects treated with serlopitant compared with placebo.
View full report: https://www.datamintelligence.com/research-report/prurigo-nodularis-treatment-market
Enquiry before buying: https://www.datamintelligence.com/enquiry/prurigo-nodularis-treatment-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
The Prurigo Nodularis Treatment Market research report elaborates on growth, size, current industry trends, and key players of the industry on the basis of in-depth data mining and industry analysis.
The content of the market study ensures intellectual insights giving a better understanding of the ideal opportunities in the Prurigo Nodularis Treatment market.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the Prurigo Nodularis Treatment include Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Merck & Co. Inc., Sanofi SA, and GlaxoSmithKline plc.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Request FREE sample copy of the report “Global Prurigo Nodularis Treatment Market” at: https://www.valuemarketresearch.com/contact/prurigo-nodularis-treatment-market/download-sampleMarket SegmentationThe broad Prurigo Nodularis Treatment has been sub-grouped into the Product, Distribution Channel and region.
The report studies these subsets with respect to the geographical segmentation.
The strategists can gain a detailed insight and devise appropriate strategies to target specific market.
The Prurigo Nodularis Treatment Market Research Report Forecast is a valuable source of insightful data for business strategists.
It provides the industry overview with recent trends, size, share, growth analysis, historical, futuristic data, revenue, demand and strategic development.The entire prurigo nodularis treatment market has been sub-categorized into product and distribution channel.
The report provides an analysis of these subsets with respect to the geographical segmentation.
This research study will keep marketer informed and helps to identify the target demographics for a product or service.Request a FREE Sample Copy of Global Prurigo Nodularis Treatment Market Report with Full TOC At: https://www.valuemarketresearch.com/contact/prurigo-nodularis-treatment-market/download-sampleBy ProductAntihistaminesCapsacin CreamCorticosteroidsEmollientsOthersBy Distribution ChannelRetail PharmaciesHospital PharmaciesOnline PharmaciesThe research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the prurigo nodularis treatment market include Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Merck & Co. Inc., Sanofi SA, and GlaxoSmithKline plc.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.This section covers regional segmentation which accentuates on current and future demand for prurigo nodularis treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
Prurigo nodularis is a skin condition that generally causes itchy and hard lumps in the form of nodules.
Prurigo nodularis can be mild or severe and may cause itching on skin.
The condition is considered to be an auto-immune disease.
Unbearable itching enforces patients to scratch the skin that causes inflammation and redness.
It may appear in other parts of the body as well.
For the treatment, patients choose the best Homeopathy Treatment and Doctor for Prurigo Nodularis in India.
Latest Prurigo Nodularis Treatment Market Report published by value market research, it provides a comprehensive market analysis which includes market size, share, value, growth, trends during forecast period 2020-2026 along with strategic development of the key player with their market share.
Further, the market has been bifurcated into sub-segments with regional and country market with in-depth analysis.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the prurigo nodularis treatment market include Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Merck & Co. Inc., Sanofi SA, and GlaxoSmithKline plc.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Prurigo Nodularis Treatment Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/prurigo-nodularis-treatment-market/download-sampleMarket DynamicsRising demand for the need for orphan drugs to treat a rare disease are the key factors that drive the market demand.
In addition to this, increasing government initiatives on healthcare awareness and infrastructure, strong investment in R activities for treatment of such diseases, and rising demand for better treatment is expected to propel the market growth during the forecast period.
Though, collaborative funding for transitional projects is anticipated to create potential opportunities for prurigo nodularis treatment market in the coming year.
